BR112014029861A2 - compostos imunogênicos e usos dos mesmos - Google Patents

compostos imunogênicos e usos dos mesmos

Info

Publication number
BR112014029861A2
BR112014029861A2 BR112014029861A BR112014029861A BR112014029861A2 BR 112014029861 A2 BR112014029861 A2 BR 112014029861A2 BR 112014029861 A BR112014029861 A BR 112014029861A BR 112014029861 A BR112014029861 A BR 112014029861A BR 112014029861 A2 BR112014029861 A2 BR 112014029861A2
Authority
BR
Brazil
Prior art keywords
immunogenic
immunogenic compounds
refers
compounds
hiv
Prior art date
Application number
BR112014029861A
Other languages
English (en)
Other versions
BR112014029861B1 (pt
Inventor
Desfontaines Dominique
Crouzet Joël
Ho Tsong Fang Raphaël
Original Assignee
Innavirvax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innavirvax filed Critical Innavirvax
Publication of BR112014029861A2 publication Critical patent/BR112014029861A2/pt
Publication of BR112014029861B1 publication Critical patent/BR112014029861B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

1/1 resumo “compostos imunogênicos e usos dos mesmos” a presente invenção se refere ao campo de vacinas direcionadas aos vírus da família do hiv. mais particularmente, se refere a um composto imunogênico que compreende um peptídeo da seguinte fórmula (i): nh2-[nt]y-p-w-n-x1-s-x2-s-n-x3-x4-x5-x6-x7-i-w-[ct]z-cooh (i), que é covalentemente ligado a uma proteína carreadora que consiste em uma proteína crm197. isso também se refere a uma composição que contém esse composto imunogênico e os usos desses compostos imunogênicos e composições para prevenção e/ou tratamento de uma condição ocasionada pela infecção de um indivíduo por um vírus hiv.
BR112014029861-0A 2012-05-31 2013-05-30 Compostos imunogênicos, composição e uso de composto BR112014029861B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305602.0 2012-05-31
EP12305602.0A EP2668959B1 (en) 2012-05-31 2012-05-31 Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein
PCT/IB2013/054482 WO2013179262A1 (en) 2012-05-31 2013-05-30 Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein

Publications (2)

Publication Number Publication Date
BR112014029861A2 true BR112014029861A2 (pt) 2017-07-25
BR112014029861B1 BR112014029861B1 (pt) 2022-05-24

Family

ID=48793339

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029861-0A BR112014029861B1 (pt) 2012-05-31 2013-05-30 Compostos imunogênicos, composição e uso de composto

Country Status (21)

Country Link
US (1) US9511136B2 (pt)
EP (2) EP2668959B1 (pt)
JP (1) JP6352251B2 (pt)
KR (1) KR102077876B1 (pt)
CN (1) CN104507496B (pt)
AU (1) AU2013269120B2 (pt)
BR (1) BR112014029861B1 (pt)
CA (1) CA2875162C (pt)
DK (1) DK2668959T3 (pt)
EA (1) EA027803B1 (pt)
ES (2) ES2528109T3 (pt)
HR (1) HRP20150058T1 (pt)
IN (1) IN2014DN10128A (pt)
MX (1) MX360206B (pt)
PL (1) PL2668959T3 (pt)
PT (1) PT2668959E (pt)
RS (1) RS53769B1 (pt)
SI (1) SI2668959T1 (pt)
UA (1) UA118542C2 (pt)
WO (1) WO2013179262A1 (pt)
ZA (1) ZA201409023B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335119A1 (en) * 2004-02-06 2014-11-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
BR112017021981A2 (pt) * 2015-04-17 2018-07-10 Biolife Science Qld Limited composição de vacina e usos da mesma
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184973A1 (en) * 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
EP4115900A1 (en) * 2021-07-05 2023-01-11 Diaccurate Novel antigens and vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
JP4696079B2 (ja) * 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
US20110305749A1 (en) * 2008-08-28 2011-12-15 Mogens Ryttergaard Duch HIV-1 Envelope Polypeptides for HIV Vaccine
US7965010B2 (en) * 2008-09-03 2011-06-21 Bose Corporation Linear motor with patterned magnet arrays
WO2010040853A1 (en) * 2008-10-10 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method

Also Published As

Publication number Publication date
EP2668959A1 (en) 2013-12-04
UA118542C2 (uk) 2019-02-11
CN104507496B (zh) 2018-08-03
ZA201409023B (en) 2016-08-31
JP2015519359A (ja) 2015-07-09
CA2875162C (en) 2021-09-14
PT2668959E (pt) 2015-02-05
WO2013179262A1 (en) 2013-12-05
HRP20150058T1 (hr) 2015-04-10
EP2854846B1 (en) 2018-09-12
EA201491969A1 (ru) 2015-04-30
EA027803B1 (ru) 2017-09-29
SI2668959T1 (sl) 2015-03-31
AU2013269120B2 (en) 2017-04-20
US20150147348A1 (en) 2015-05-28
PL2668959T3 (pl) 2015-04-30
CA2875162A1 (en) 2013-12-05
EP2854846A1 (en) 2015-04-08
IN2014DN10128A (pt) 2015-08-21
ES2528109T3 (es) 2015-02-04
EP2668959B1 (en) 2014-11-05
JP6352251B2 (ja) 2018-07-04
BR112014029861B1 (pt) 2022-05-24
RS53769B1 (en) 2015-06-30
US9511136B2 (en) 2016-12-06
CN104507496A (zh) 2015-04-08
ES2701084T3 (es) 2019-02-20
MX2014014526A (es) 2015-06-02
KR102077876B1 (ko) 2020-02-14
KR20150032266A (ko) 2015-03-25
MX360206B (es) 2018-10-24
DK2668959T3 (en) 2015-01-26
AU2013269120A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
BR112014029861A2 (pt) compostos imunogênicos e usos dos mesmos
EA201491548A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
BR112018067964A2 (pt) agentes antivirais para hepatite b
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
UA118010C2 (uk) Інгібітори реплікації вірусів грипу
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112012014899A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
BR112016000975A8 (pt) esteróides neuroativos, composições os compreendendo e uso dos mesmos
EA201201321A1 (ru) Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CL2015001304A1 (es) Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
BR112013026308A2 (pt) Compostos de benzeno substituídos
BR112015019126A2 (pt) Vacina de combinação para vírus sincicial respiratório e influenza
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112018068640A2 (pt) derivados de indolina substituídos como inibidores da replicação viral do dengue
BR112015017749A2 (pt) composição de catalisador para a polimerização de olefinas
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
EP2538946A4 (en) ANTIVIRAL FORMULATIONS
BR112017025435A2 (pt) vetores de influenza atenuada para a prevenção e/ou o tratamento de doenças infecciosas e para o tratamento de doenças oncológicas
PH12019502376A1 (en) Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
BR112014015582A8 (pt) compostos antivirais
BR112015000392A2 (pt) novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/05/2013, OBSERVADAS AS CONDICOES LEGAIS